Buletin Farmatera
Vol 5, No 1 (2020)

ANTIHIPERGLICEMIC THERAPY COMPLIANCE WITH HbA1C LEVELS IN TYPE 2 DIABETES MELLITUS PATIENTS AMONG PEKANBARU PROLANIS PARTICIPANTS

Dimas Pramita Nugraha (Departement of Pharmacology, Medical Faculty, University of Riau)
Eni Karmila Asni (Departement of Biochemistry, Medical Faculty, University of Riau)
Ligat Pribadi Sembiring Pribadi Sembiring (Departement of Internal Medicine, Medical Faculty, University of Riau)



Article Info

Publish Date
18 Feb 2020

Abstract

One of the pillars in the management of Type 2 Diabetes Mellitus (DM) is pharmacotherapy, i.e. the use of antihyperglycemic drugs. Success in DM management is influenced by patient compliance to the pharmacotherapy given. One indicator of controlling Type 2 DM is HbA1c levels. This study aimed to analyze the relationship between antihyperglycemic therapy compliance and the HbA1c levels in Type 2 DM patients in the Chronic Disease Management Program in Pekanbaru. Method. This was a cross-sectional study. Samples were taken by consecutive sampling method. Laboratory examination was carried out to obtain HbA1c levels, the value of which was categorized controlled if <7%. The compliance with the use of antihyperglycemic drugs was assessed using Medication Possession Ratio (MPR). Patients were considered compliant if they had an MPR of ≥80%. Data were analyzed using the Fisher Exact test. Results. Most of the 48 patients had uncontrolled HbA1c levels (87,5%). The level of non-compliant patients was also very high (91,7%). This study showed a significant relationship between pharmacotherapy compliance and HbA1c levels (p <0.05). Discussion. There was a relationship between pharmacotherapy compliance and the level of HbA1c in Type 2 DM patients.  Physicians should pay more attention to patients with low compliance as it may increase the risk to a high HbA1c level

Copyrights © 2020